Biomarkers of intake for coffee, tea, and sweetened beverages by Rothwell, Joseph A et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Biomarkers of intake for coffee, tea, and sweetened beverages
Rothwell, Joseph A; Madrid-Gambin, Francisco; Garcia-Aloy, Mar; Andres-Lacueva, Cristina;
Logue, Caomhan; Gallagher, Alison M; Mack, Carina; Kulling, Sabine E; Gao, Qian; Praticò,
Giulia; Dragsted, Lars Ove; Scalbert, Augustin
Published in:
Genes and Nutrition
DOI:
10.1186/s12263-018-0607-5
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Rothwell, J. A., Madrid-Gambin, F., Garcia-Aloy, M., Andres-Lacueva, C., Logue, C., Gallagher, A. M., ...
Scalbert, A. (2018). Biomarkers of intake for coffee, tea, and sweetened beverages. Genes and Nutrition, 13,
[15]. https://doi.org/10.1186/s12263-018-0607-5
Download date: 03. Feb. 2020
Rothwell et al. Genes & Nutrition  (2018) 13:15 
https://doi.org/10.1186/s12263-018-0607-5REVIEW Open AccessBiomarkers of intake for coffee, tea, and
sweetened beverages
Joseph A. Rothwell1, Francisco Madrid-Gambin2, Mar Garcia-Aloy2,3, Cristina Andres-Lacueva2,3, Caomhan Logue4,
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and Augustin Scalbert1*Abstract
Non-alcoholic beverages are important sources of nutrients and bioactive compounds that may influence human
health and increase or decrease the risk of chronic diseases. A wide variety of beverage constituents are absorbed
in the gut, found in the systemic circulation and excreted in urine. They may be used as compliance markers in
intervention studies or as biomarkers of intake to improve measurements of beverage consumption in cohort
studies and reveal new associations with disease outcomes that may have been overlooked when using dietary
questionnaires. Here, biomarkers of intake of some major non-alcoholic beverages—coffee, tea, sugar-sweetened
beverages, and low-calorie-sweetened beverages—are reviewed. Results from dietary intervention studies and
observational studies are reviewed and analyzed, and respective strengths and weaknesses of the various identified
biomarkers discussed. A variety of compounds derived from phenolic acids, alkaloids, and terpenes were shown to
be associated with coffee intake and trigonelline and cyclo(isoleucylprolyl) showed a particularly high specificity for
coffee intake. Epigallocatechin and 4′-O-methylepigallocatechin appear to be the most sensitive and specific
biomarkers for green or black tea, while 4-O-methylgallic acid may be used to assess black tea consumption. Intake
of sugar-sweetened beverages has been assessed through the measurement of carbon-13 enrichment of whole
blood or of blood alanine in North America where sugar from sugarcane or corn is used as a main ingredient. The
most useful biomarkers for low-calorie-sweetened beverages are the low-calorie sweeteners themselves. Further
studies are needed to validate these biomarkers in larger and independent populations and to further evaluate
their specificity, reproducibility over time, and fields of application.
Keywords: Non-alcoholic beverages, Coffee, Tea, Sugar-sweetened beverages, Low-calorie-sweetened beverages,
Biomarkers, IntakeBackground
Human adults consume about 3 to 4 l of water per day,
which originate from plain water, solid foods, and other
beverages like coffee, tea, soda, fruit juices, sport and
energy drinks, milk, and alcoholic beverages [1]. Beside
water, non-alcoholic beverages such as coffee and tea are
also a source of other constituents like caffeine, chloro-
genic acids, diterpenes, and diketopiperazines in coffee
[2], theanine, catechins, theaflavins, thearubigins and
flavonols in tea [3], sucrose or high-fructose corn syrup* Correspondence: scalberta@iarc.fr
1International Agency for Research on Cancer (IARC), Nutrition and
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(http://creativecommons.org/publicdomain/ze(HFCS) in sodas, and low-calorie sweeteners (LCSs) in
low-calorie-sweetened beverages (LCSBs) which may
influence health in a positive or negative way.
Although coffee drinking was initially thought to in-
duce negative effects on health, for example, increasing
blood pressure and the risk of cardiovascular disease risk
in some cohorts [4, 5], the main interest in recent years
is the potential for positive health effects. These include
plausible reductions in risk of type 2 diabetes, Parkinson
disease, Alzheimer’s disease, and liver and colorectal
cancer [6–10]. Tea consumption has been associated
with a reduction of the risk of chronic diseases and more
particularly cardiovascular diseases, type 2 diabetes,
cancers, and neurodegenerative diseases [11–14]. Com-
pounds like sugars in sodas may provide an excess ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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diseases [15]. Given the overconsumption of free sugars,
particularly from SSBs, the use of LCSBs has increased
over the years as a strategy for reducing the free sugar
content of the diet while maintaining palatability and re-
search interest to date has focused on assessing the ef-
fect of LCSB consumption on a variety of health
outcomes such as metabolic health, weight management,
and renal impairment [16, 17].
Despite large efforts in unraveling these health effects
of non-alcoholic beverages on health in epidemiological
studies, some of these effects are not fully consistent
between studies, and it has been suggested that this lack
of agreement could be associated with the traditional
methods used to assess beverage consumption [18].
Beverage consumption is most often measured with
self-administered questionnaires, and these measure-
ments are known to be prone to random or systematic
errors which may prevent the detection of associations
of intake with disease outcomes [19]. These errors are
linked to limitations in the capacity of subjects to
accurately describe their beverage intake and to difficul-
ties in accounting for variations in the nature of the
beverages consumed within or between populations. For
example, concentrations of polyphenols in coffee and in
tea vary with the type of coffee beans or tea leaves and
with the method of coffee brewing or tea leaf infusion,
information most often not recorded in dietary
questionnaires.
In contrast to questionnaires, biomarkers are object-
ive measures that provide estimates of beverage in-
take [20–22]. They are directly derived from beverage
constituents absorbed in the gut during digestion.
Thus, they provide more direct estimates of exposure
to beverage constituents and are notably independent
of the dilution of the beverages, or on any aspect of
the recipes used for their preparation. Biomarkers of
beverage intake can be identified using two separate
approaches. Initially, biomarkers were hypothesized
based on knowledge of beverage constituents and their
metabolism. Beverages are fed to volunteers in controlled
intervention studies and known metabolites of interest
measured in biofluids to test for increases with intake.
Until a few years ago, this targeted approach was the only
viable method of biomarker discovery. More recently, me-
tabolome profiling has taken precedence as a more com-
prehensive and agnostic approach. Rather than measuring
known compounds only, biofluids are profiled to measure
the relative intensities of as many signals as can be de-
tected, either by nuclear magnetic resonance (NMR) or
mass spectrometry coupled to liquid or gas chromatog-
raphy (LC-MS or GC-MS). Signals associated with intake
of the target food across the most possible subjects are
retained as candidate biomarkers.Initial metabolome profiling studies used an interven-
tion design with a standardized dose and controlled diet,
but more sensitive analytical techniques have enabled
the analysis of biofluids from free-living subjects who
have reported their beverage intakes via dietary ques-
tionnaires. This approach has some advantages and limi-
tations. It encourages the discovery of biomarkers that
are valid in the presence of interfering dietary factors
and that also account for differences in the time period
between beverage intake and biofluid collection. On the
other hand, finding new biomarkers may be prevented
by the limited accuracy of self-reported dietary intake
data. Whatever the discovery approach, biomarkers can
only be considered valid for the populations and
biofluids in which they are discovered as different popu-
lations drink different brands or brews of a beverage
with different compositions.
The purpose of this review is to describe the various
biomarkers proposed to evaluate intake of some non-
alcoholic beverages, including coffee, tea, sugar-
sweetened beverages (SSBs), and LCSBs, all beverages
that have raised much interest for being widely con-
sumed worldwide and for their effects on the risk of
various chronic diseases. Other non-alcoholic beverages
such as fruit juices and milk are discussed in other
chapters in this special volume. For each beverage, the
main metabolites formed from their constituents and
identified in blood or urine in human dietary interven-
tion studies as putative biomarkers are first described.
Their eventual detection in observational studies and re-
spective value as intake biomarkers is then discussed.
Materials and methods
The reviewing process made was described in details re-
cently [23] and use all elements of the PRISMA state-
ment [24] that were relevant for a literature search on
dietary biomarkers. Original research papers and reviews
were searched for in PubMed, Scopus, and ISI Web of
Knowledge using the following search terms: (bio-
marker* OR marker* OR metabolite* OR biokinetics OR
biotransformation) AND (human* OR men OR women
OR male OR female OR patient* OR volunteer* OR par-
ticipant*) AND (urine OR plasma OR serum OR blood
OR excretion) AND (intake OR meal OR diet OR inges-
tion OR consumption OR eating OR drink* OR adminis-
tration) AND (‘name of beverage’). Name of beverages
were (coffee), (tea), or (diet soda OR diet beverage* OR
soft drink* OR artificial* sweet* beverage* OR low sugar
beverage* OR low calorie sweet* beverage*).
The research was limited to papers in English lan-
guage, and no restrictions were applied to publication
date. End-date of search was April 2016, January 2017,
June 2016, and December 2016 for coffee, tea, SSBs, and
LCSBs, respectively. The research papers identifying or
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selected by one or more skilled researchers from the list
of retrieved references in the process outlined in
Additional file 1: Figure S1. Additional papers were iden-
tified from reference lists in these papers and from re-
views or book chapters identified through the search.
For each potential biomarker identified, an additional
search was conducted with (“the name and synonyms of
the compound” OR “the name and synonyms of any par-
ent compound”) AND (biomarker* OR marker* OR
metabolite* OR biokinetics OR biotransformation) to
identify potential other foods containing the biomarker
or its precursor. In this second step, Scifinder and
Google Scholar were also used as search platforms,
as well as the databases listed above. This second
search was used to evaluate the apparent specificity
of the marker.
Results and discussion
Biomarkers have been systematically searched for in the
scientific literature independently for the four types of
non-alcoholic beverages (coffee, tea, SSBs, and LCSBs).
The literature was particularly abundant for biomarkers
of coffee and tea intake (Additional file 1: Figure S1).
Results are successively presented below.
Coffee biomarkers
Coffee metabolites in controlled intervention studies
Many controlled intervention studies have been
performed on coffee to study the metabolism of known
coffee constituents (Table 1). Most aimed to study the
metabolism of caffeoylquinic acid derivatives. Typically,
in these studies, a small number of subjects consumed
coffee after a washout period, and blood or urineTable 1 Metabolites identified in human intervention studies on co
Beverage No. subjects Sample type Analytical method Enzymati
Instant coffee
(repeated intake)
5 Urine HPLC Yes
Instant coffee 9 Urine LC-MS Yes
Coffee 13 Urine CE-MS No
Instant coffee 11 Plasma, urine LC-MS No
Filter coffee 9 Urine LC-MS No
Filter coffee 13 Plasma LC-MS No
Instant coffee 11 Plasma, urine LC-MS No
Coffee
(repeated intake)
8 Urine 1H-NMR Nosamples were taken at intervals for analysis. In early
studies, metabolites were quantified by HPLC after en-
zymatic hydrolysis of glucuronide and sulfate conjugates.
Isoferulic acid concentrations most markedly increased
in urine samples taken periodically of volunteers repeat-
edly dosed with coffee and was thus proposed as a po-
tential intake biomarker [25]. Another such intervention
indicated that caffeic acid, as well as the microbial me-
tabolite m-coumaric acid, appears in 24-h urine after
coffee intake [26]. With mass spectrometers, many more
metabolites derived from coffee chlorogenic acids were
later characterized without enzyme treatment. For
example, individual caffeic and ferulic acid conjugates
were measured by LC-MS in the plasma and urine of
subjects fed instant coffee [27]. Dihydroferulic acid
4-O-sulfate and dihydrocaffeic acid 3-O-sulfate attained
the highest plasma concentrations after coffee intake.
Dihydrocaffeic acid 3-O-sulfate and feruloylglycine were
reported as the most sensitive urinary biomarkers of in-
take. Further, in a double-blind randomized controlled
trial investigating bioavailability of chlorogenic acids
from coffee, all chlorogenic acid metabolites increased in
a dose-dependent manner in plasma and urine after the
administration of coffee containing three different levels
of chlorogenic acids [28]. Concentrations of caffeic and
ferulic acid sulfates were most markedly increased, but
coffee intake also caused increases of intact caffeoylqui-
nic acids and sulfated caffeoylquinic acid lactones.
3-Feruloylquinic acid, in both 24-h urine and plasma,
was highly correlated with the caffeoylquinic acids con-
sumed from coffee (Spearman r = 0.81 and r = 0.73,
respectively).
Despite providing a wealth of information on potential
markers of coffee intake, the main purpose of theseffee
c hydrolysis Discriminating metabolites/candidate biomarkers Reference
Ferulic, isoferulic, dihydroferulic, vanillic acids,
3-hydroxyhippuric acid
[25]
Chlorogenic acid, caffeic acid, m-coumaric acid [26]
Coumaric acid, caffeic acid [127]
Ferulic and dihydroferulic acid sulfates (blood
and urine), feruloylglycine (urine only)
[27]
Trigonelline, N-methylpyridium [35]
Trigonelline, dimethylxanthines, methylxanthines,
dihydroferulic acid, dihydrocaffeic acid sulfate,
ferulic acid glucuronide, ferulic acid sulfate,
ferulic acid, dihydroferulic acid sulfate,
dihydroferulic acid glucuronide, N- feruloylglycine
[29]
3-, 4- and 5-Feruloylquinic acid, 3 and 4-
Caffeoylquinic acid lactone sulfate (urine and
plasma), isoferulic acid-3-glucuronide (urine only)
[28]
2-Furoylglycine [30]
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the metabolism of hydroxycinnamic acid derivatives ra-
ther than search for novel biomarkers of intake. Other
authors have followed the appearance of a variety of
coffee compounds in blood or urine in subjects adminis-
tered a standardized dose of coffee [29]. Dihydroferulic
acid conjugates, trigonelline, caffeine, and its primary
metabolites were found to persist in plasma for long
enough that they should never be fully cleared in indi-
viduals drinking three cups of coffee over a day. N-2-fur-
oylglycine was identified as a promising biomarker of
coffee intake after the untargeted NMR profiling of spot
urine samples from five volunteers administered a dose
of espresso coffee [30]. Highest concentrations were
observed two hours after intake. N-2-furoylglycine is
derived from furans formed during coffee roasting.
Biomarkers of coffee intake in observational studies
Markers uncovered in controlled intervention studies
may be sensitive but not sufficiently specific to the food
of interest since other possible food sources of these me-
tabolites are excluded throughout the intervention. Caf-
feoylquinic and feruloylquinic acids and their derivatives,
for example, are also present in fruits, vegetables, and
grains [31]. Although coffee is the principal dietary
source, high intake of other confounding foods could
lead to inaccurate estimates of intake. Biomarkers lack-
ing specificity are better excluded in observational stud-
ies, in which subjects consume their usual diets. Food
intake is estimated with dietary questionnaires before
blood or urine collection. The first such study on coffee
hypothesized that urinary isoferulic acid, a metabolite of
caffeoylquinic and caffeic acids, would reflect habitual
coffee intake (Table 2) [32]. Study participants, consum-
ing their usual diets, recorded coffee intake via question-
naires, and 24-h pooled urine was collected. Urinary
isoferulic acid excretion varied substantially between cof-
fee consumers and was not strongly related to coffee in-
take as reported by food frequency questionnaire (FFQ)
(r = 0.26) or 24-h dietary recall (r = 0.18). Another study
on 53 free-living French subjects showed a stronger
correlation (r = 0.63, p < 0.001) between 5-caffeoylquinic
acid concentrations in spot urine and coffee intake, but
this association was not statistically significant when
tested in 24-h urine [33]. High correlations were ob-
served between coffee intake and caffeic acid (r = 0.65),
protocatechuic acid (r = 0.60), and ferulic acid (r = 0.58)
concentrations measured in 24-h urine collected in 475
adult participants from the European Prospective
Investigation into Cancer and Nutrition (EPIC)
cross-sectional study [34].
Later, metabolomic studies found novel markers of
coffee intake in observational studies using untargeted
approaches. In a first such study, N-methylpyridiniumand trigonelline, products of the coffee roasting process,
were found to best distinguish coffee drinkers from
non-coffee drinkers (after analysis of urine by LC-MS)
[35]. Both compounds remained elevated in urine for at
least 2 days after coffee consumption and were thus
proposed as stable biomarkers of intake. N-methylnicoti-
namide also distinguished the two groups, although it
was not considered specific to coffee intake, being a
metabolite of niacin found in a wide range of foods. In
another study, dihydrocaffeic acid and its 3-glucuronide,
measured in 24-h urine by LC-MS, was found to
discriminate groups of high- and low-coffee consumers
(identified with a food frequency questionnaire) with
high sensitivity and specificity [36]. A later cross-
sectional study in 481 subjects of the EPIC cohort, also
using 24-h urine samples, showed significant correla-
tions between concentrations of 16 phenolic acids,
mostly glucuronide or sulfate esters, with acute coffee
intake as estimated with 24-h dietary recalls [37]. Dihy-
droferulic acid sulfate concentrations correlated most
strongly with coffee intake whether assessed by FFQ (r =
0.62) or 24-h dietary recall (r = 0.52). Dihydroferulic acid
sulfate, feruloylquinic acid glucuronide, ferulic acid sulfate,
and guaiacol glucuronide were the metabolites whose
measured intensities best classified subjects into the high-
est or lowest quintiles of coffee intake, with a receiver op-
erating characteristic (ROC) area under the curve (AUC)
for the predictive model > 94%. Non-phenolic metabolites
were not investigated in this study.
The use of 24-h urine samples yields the widest range
of potential biomarkers, as all coffee metabolites accu-
mulate in urine after coffee intake regardless of metabol-
ite pharmacokinetics. Biomarkers identified in 24-h
urine samples cannot be assumed to be effective markers
when measured in spot urine or in blood samples taken
at a single time point since many food-derived metabo-
lites are excreted rapidly after absorption. A few authors
have searched for markers of coffee intake in spot urine
or blood collections (Table 2). For example, biomarkers
of coffee intake were searched for in morning spot urines
of French subjects from the SUVIMAX cross-sectional
study [38]. The intensities of several coffee-derived
metabolites accurately classified consumers into high- and
low-intake groups (respectively 183–540 and vs. 0 mL/
day, as measured with repeated 24-h dietary recalls and a
food frequency questionnaire). The most effective of these
were the diterpene atractyligenin glucuronide (r = 0.534,
ROC AUC= 0.98), the cyclic amino acid cyclo(isoleucyl-
prolyl) (r = 0.543, ROC AUC= 0.969) and the caffeine me-
tabolite 1-methylxanthine (r = 0.561, ROC AUC= 0.965).
Also, urinary concentrations of 1,7-dimethyluric acid,
1-methyluric acid, and trigonelline each classified subjects
with an excellent sensitivity and specificity (ROC AUC >
0.9). Combining cyclo(isoleucylprolyl), 1-methylxanthine,
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creased classification performance relative to any one sin-
gle compound. Hippuric acid was elevated in the urine of
coffee consumers, while caffeoylquinic acid-derived me-
tabolites were not reported as discriminants in this study.
Two further studies have identified biomarkers of coffee
intake in blood. Trigonelline, 1-methylxanthine, and para-
xanthine were identified as serum biomarkers of coffee in-
take when comparing high- (> 2.5 cups/day) and low- (<
2.5 cups/day) coffee drinkers in an American-nested
case-control study, along with N-2-furoylglycine and cat-
echol sulfate [39]. A more detailed study on coffee in the
same cohort additionally reported that plasma trigonelline
(partial r = 0.608) and quinic acid (partial r = 0.59) concen-
trations best correlated with coffee intake as reported by
FFQ [10]. In contrast, concentrations of unmetabolized
caffeine correlated moderately with coffee intake (partial r
= 0.327).
The studies described above proposed biomarkers of
intake exclusively in urine, plasma, or serum. A small
number of studies have considered coffee-derived me-
tabolites in other biospecimens. For example, after a
dose of coffee, a Japanese group was able to measure
caffeine and three isomers of dimethylxanthine in finger-
prints [40]. Also, pyridine was found to increase in
breath after consumption of a large cup of espresso [41].
Such techniques may not be applicable to epidemio-
logical studies at present but represent possible future
alternatives to measuring biomarkers of coffee intake in
blood and urine.
In summary, many exogenous blood and urinary me-
tabolites have been proposed as coffee intake markers
but their validity depends on study design, study popula-
tion, biofluid, and analytical method. In intervention
studies where urine or blood samples are taken shortly
after the administration of coffee, hydroxycinnamic acid
derivatives such as caffeic and dihydroferulic acid (and
their phase II conjugates) have been most commonly
proposed as biomarkers of coffee intake. Most recent
studies in free-living subjects suggest that several phen-
olic acids (ferulic, isoferulic, dihydroferulic, caffeic, and
dihydrocaffeic acids and their glucuronides and sulfate
esters), alkaloids (caffeine, trigonelline, and their metab-
olites), cyclo(isoleucylprolyl), and atractyligenin glucuro-
nide, measured in urine, are the most sensitive and
specific biomarkers of coffee intake. Fewer studies in
free-living subjects were conducted on blood and trigo-
nelline, and quinic acid were found to best correlate with
coffee intake.
Still, it will be important to check the specificity of
these biomarkers in the populations where implemented
as the levels of coffee intake and the impact of possible
confounders may vary between populations. Indeed,
some of these biomarkers like caffeine or ferulic acidmay also arise from other dietary sources such as tea or
soft drinks for caffeine or wholegrain cereals for ferulic
acid. Trigonelline and cyclo(isoleucylprolyl) or their pre-
cursors may be preferred considering their high specifi-
city for coffee.
Tea biomarkers
Tea metabolites in controlled intervention studies
Metabolism and pharmacokinetics of catechins have been
studied in a large number of intervention studies with
green or black tea (Table 3). The main compounds de-
tected in biofluids after green tea ingestion are catechins,
and their metabolites formed in phase II biotransforma-
tions (methylation, glucuronidation, and sulfation) and
ring-fission reactions. EGCG, EGC, ECG, and EC were
the main compounds detected in plasma. They are quickly
absorbed, and peak concentrations are observed about 2 h
after ingestion [42]. Tea catechins are also quickly ex-
creted, and their elimination half-lives usually do not ex-
ceed 3 h. EGC is the most abundant catechin in plasma
after tea intake, mainly found in its glucuronidated form
[42]. EGC is also methylated in the liver, and 4′-O-methy-
l-EGC is found in both sulfated and glucuronidated forms.
Galloylated catechins (EGCG and ECG) are present in
plasma in their non-conjugated forms.
Catechins not absorbed in the small intestine reach
the colon where they can be degraded by the microbiota
into low-molecular weight metabolites such as hydroxy-
phenylvalerolactones, hydroxyphenylvaleric acids, phen-
olic acids, and hippuric acid. These metabolites show
longer elimination half-lives in urine where they persist
for 48 h after tea intake [43].
Most studies showed a linear relationship between
plasma concentrations or urine excretion of tea catechins
and the ingested dose [44–48] although concentrations of
some catechins were also shown to reach a plateau at a
high level of intake in some studies [49, 50].
Many untargeted metabolomic studies have been
conducted to elucidate additional candidate biomarkers of
tea intake [51–53]. In a placebo-controlled cross-over inter-
vention study based on high-resolution mass spectrometry,
12 male subjects consumed a single capsule of tea extract
(2.65 g) or a placebo after 1 day of a polyphenol-poor diet
[54]. Fifty-nine polyphenol metabolites were identified and
increased in concentration after black tea ingestion.
These metabolites were catechins, phenolic acids, valero-
lactones, and simple phenols, most in the form of glucuro-
nides and sulfate esters. The highest concentrations in
plasma were observed within 1–4 h (catechins, kaemp-
ferol, gallic acid) or 5–10 h (microbial metabolites such as
phenylvalerolactones, pyrogallol, and hippuric acid),
suggesting that they would be better indicators of tea in-
take if measured in 24-h urine samples rather than spot
urine samples.
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green and black tea. In particular, 4-O-methylgallic acid,
formed by O-methylation of gallic acid, has frequently
been reported in both urine and plasma after black tea
intake [55–57]. This metabolite is also detected in urine
after green tea intake but in much lower concentrations
[58]. This difference in concentrations is explained by
the low content of gallic acid in green tea when com-
pared to black tea. Measurement of 4-O-methylgallic
acid in urine or plasma could thus be useful to differen-
tiate consumption of black and green tea, particularly if
used in combination with catechins more abundant in
green tea than in black tea [59] and present at higher
concentrations in plasma or urine after consumption of
green tea when compared to black tea [49, 60–62].
Theaflavins and thearubigins are abundant in black tea
and absent from green tea; however, their high molecu-
lar weight considerably limits or prevents their absorp-
tion in the gut [63] and they therefore cannot be used as
biomarkers of black tea intake.
Catechin metabolites formed by the gut microbiota are,
in comparison with catechins or gallic acid, less useful as
biomarkers of tea intake. Some of these metabolites (some
phenolic acids and hippuric acid) were present in plasma
in the absence of tea consumption [54]. This is explained
by the existence of precursors of these metabolites in
other dietary sources such as coffee, cocoa, fruits, or vege-
tables beside tea [64–66]. Other metabolites derived from
tea catechins such as 5-(3′,4′,5′-trihydroxyphenyl)-γ-va-
lerolactone, 5-(3′,4′-dihydroxyphenyl)- γ-valerolactone,
and/or 5-(3′,5′-dihydroxyphenyl)- γ-valerolactone may be
more specific for tea intake [48, 67]. However, formation
of these metabolites from catechins shows high interindi-
vidual variations, compromising their potential use as
biomarkers of intake [68]. Similarly, other tea constituents
such as quercetin or caffeine may also be of limited utility
as biomarkers due to their abundance in other foods and
beverages [69, 70].
Biomarkers of tea intake in observational studies
As previously highlighted, observational studies allow
the investigation of biomarker sensitivity and specificity.
In the Shanghai Cohort Study, EGC, 4′-O-methyl-EGC,
EC, and two phenylvalerolactones measured in urine
were significantly associated with self-reported tea intake
[71, 72]. In another study carried out in 481 subjects
from the EPIC cohort, metabolic profiles were com-
pared in 24-h pooled urine samples by high-resolution
MS in tea consumers and non-consumers (identified with
24-h dietary recalls) [37]. Several phenolic compounds
were found to be associated with recent tea intake as
assessed with a 24-h dietary recall. The compound that
best distinguished non- and high consumers was found to be
4-O-methylgallic acid (ROC AUC=0.84). 4-O-Methylgallicacid was also associated with habitual tea intake as assessed
with a FFQ despite its short-elimination half-life, and this
was explained by frequent tea intake in this population.
However, some confounding with red wine intake was also
observed. Other polyphenol metabolites were also found to
be associated with tea intake in the same study (methyl(epi)-
catechin sulfate, dihydroxyphenyl-γ-valerolactone sulfate,
hydroxyphenylvaleric acid glucuronide, and pyrogallol sul-
fate), but they may not be more specific for tea than
4-O-methylgallic acid, as other dietary sources of the same
polyphenol metabolites are also known. Excretion of catechin
metabolites in urine were also found to be correlated with in-
take of chocolate products, apples, and pears. Pyrogallol sul-
fate has also been identified in plasma after intake of nuts
[73] or mixed berry fruit [74]. In another cross-sectional
study, 24-h urinary kaempferol was correlated with tea intake
(r= 0.41; p < 0.01) [75], but kaempferol was also found to be
correlated with onion in another study [76]. Therefore, most
of these markers associated with tea intake may not be spe-
cific enough for tea, depending on the possible consumption
of confounding foods in the population considered.
Some catechins might be the most specific biomarkers
for tea intake. Three catechins, EGCG, EGC, and ECG,
are mainly or exclusively found in tea according to the
Phenol-Explorer database [59]. Galloylated catechins
EGCG and ECG and their methylated metabolites have
been detected in both plasma and urine in tea interven-
tion studies, but they may be more difficult to measure
in population studies due their limited absorption in the
gut when compared with other catechins [77, 78]. In
summary, EGC and its phase II derivative 4′-O-methy-
l-EGC have been measured in several cohort studies and
might be a useful biomarker for green and black tea in-
take [71, 72]. 4-O-Methylgallic acid, a metabolite of
gallic acid (particularly abundant in black tea), has been
associated with black tea consumption in both interven-
tion and observational studies (Tables 3 and 4). Ratio of
4-O-methylgallic acid over EGC is expected to be higher
in black tea consumers when compared to green tea
consumers and could help to discern which of the two
types of tea has been consumed. A similar approach
using ratios of specific alkylresorcinols was used for
discriminating between wholegrain wheat and rye in-
takes [79, 80]. Other constituent characteristic of tea like
theanine have not received much attention and should
also be tested as possible biomarkers of tea intake.
Biomarkers of tea intake are summarized in Table 4.
Sugar-sweetened beverage biomarkers
Identification and validation of markers reflecting the
consumption of SSBs are an important task to better as-
sess the association between the consumption of SSBs
and related health effects. Major challenges to identify
such biomarkers are linked to the broad definition of
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One major point is the nature of the caloric sweeteners
used. Beverages containing added caloric sweeteners
such as sucrose or high-fructose corn syrup (HFCS) are
the main types of SSB. These beverages form a very het-
erogeneous group comprising soft drinks, fruit drinks,
sports drinks, energy drinks, flavored water drinks, and
iced teas [81–83]. Given this diversity of products and
their different composition, having specific markers that
reflect the intake of individual products or the total daily
consumption of SSBs is challenging.
The dominating ingredient in all SSBs is, by definition,
the added sugar. Exposure markers for the intake of sugar
have been described using two different approaches, either
through the measurement of the carbon isotope ratio
13C/12C (expressed as δ13C value) or through the deter-
mination of sugars in urine. The first approach is based
on the different discrimination against carbon dioxide
formed from the 13C and 12C isotopes in plants. Crop spe-
cies have been classified as C3 and C4 plants depending
on their photosynthetic pathway. The photosynthetic
pathway of C3 plants like sugar beet discriminates against
13CO2 compared with
12CO2, and thus, the resulting plant
mass carbon has a lower 13C/12C ratio than atmospheric
CO2. In contrast, the C4 pathway is almost non-
discriminating against 13C, resulting in a plant mass
higher in 13C compared to C3 plants. Sugarcane and corn,
the main sources for sugar production in the USA, are C4
crops. As a consequence, sugar from these crops is
enriched in 13C, compared to sugar produced by C3
plants. This enrichment can be seen in whole human bios-
pecimens or specific metabolites in these biospecimens
after consumption of sugars from C4 plants.
The 13C/12C isotope ratio of blood plasma, finger-prick
blood, or of the amino acid alanine either from hair
protein or red blood cells have been proposed in various
studies to predict intake of SSBs and added sugar in the
USA (Table 5) [84–88]. However, this approach also has
limitations depending on the nature of the sugar sourcesTable 5 Biomarkers of intake for sugar-sweetened beverages discov
No. subjects Analytical method Sample type Discrimin
biomarke
144 IRMS Serum δ13C
60 IRMS Blood δ13C
68 GC-IRMS Red blood cells δ13C of al
68 IRMS Red blood cells,
plasma, hair
δ13C
68 IRMS Fasting plasma δ13C of g
257 IRMS Blood δ13C
565 1H-NMR Urine Formate (
(HMDB00
isocitrateconsumed in various populations. While in the USA,
added sugar is mostly derived (78%) from sugarcane or
corn [89], the situation in Europe is the opposite with
around 80% added sugar derived from the C3 plant sugar
beet [90]. In consequence, the use of 13C as a potential ex-
posure marker for added sugar or SSBs is limited to the
USA. Additionally, 13C in whole blood is also influenced
by the intake of corn products and meat from livestock
fed on corn, and thus, the intake assessment of sugar
might be confounded. Two methods have been described
to correct for these confounding food items. The first
method uses nitrogen-15 which is elevated in marine
foods as well as in meat products. Therefore, it was sug-
gested to use this second isotopic marker as control for
the intake of animal protein [86, 87, 91, 92]. Nash et al.
[87, 92] found favorable results in a study population of
Yup’ik Eskimos consuming low amounts of sugar from
sources not 13C-enriched such as sugar beet, honey, fruits,
or dairy products, but high amounts of fish and marine
mammals compared to other US populations. They were
able to explain three times as much variation in the sweet-
ener intake by using a model including both the carbon
and nitrogen isotope ratios than by using δ13C alone. In
contrast, Fakhouri et al. [86] and Hedrick et al. [91] found
no significant improvement in their results after correct-
ing for the animal protein intake using nitrogen-15 in a
population where more corn-fed meat is consumed. The
second method to correct for confounders is based on the
use of a specific metabolite to measure 13C, which favors
the incorporation of glucose carbon like alanine as
described by Choy et al. [84]. They found no association
between the 13C of alanine and dietary confounders like
commercial meat, fish, and corn products. At the
same time, they found that a dual-isotope model
using 13C and 15N in red blood cells was associated
with meat intake as well as sweeteners. The use of alanine
as a specific metabolite shows favorable results in this re-
spect, but further research is needed, especially concern-
ing different populations.ered in observational studies
ating metabolites/candidate
rs (HMDB ID)
Association with Reference
24-HDR (× 2) [86]
4-day dietary record [85]
anine (HMDB0000161) 24-HDR (× 2) [84]
24-HDR [87]
lucose (HMDB0000122) 24-HDR [87]
24-HDR (× 3), 4-day
dietary record
[91]
HMDB0000142), citrulline
00904), taurine HMDB0000251,
(HMDB0000193)
4-day dietary record [95]
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uses urinary sucrose and fructose as exposure markers
[93, 94]. Details on the different intervention studies and
surveys were recently reviewed [93]. For this exposure
marker, no information on its applicability for SSBs is
currently available.
Both approaches, the carbon isotope ratio of different
biospecimens and urinary fructose and sucrose, show
promise as exposure markers for sugar and sucrose in-
take. However, sugar alone does not appear suitable as
an exposure marker for SSB consumption because it is
also contained in hundreds of other food items and is
thus not specific. The use of an exposure marker for
sugars in combination with additional substances used
as ingredients might prove to be more specific. However,
ingredients used in SSBs vary depending upon the type
of SSB. Citric acid is added to many types of widely dis-
tributed SSBs as acidity regulator. However, citric acid
seems not suitable as a marker for SSB consumption
since it is produced in large quantities in the human me-
tabolism. Moreover, it also naturally occurs in large con-
centrations in fruits and fruit juices. Other typical
ingredients in SSBs are natural or artificial flavors such
as ginger extract for ginger ale or caffeine for cola type
beverages. Using these compounds or their metabolites
as markers would consequently only cover specific sub-
groups of SSBs. Their specificity should also be carefully
assessed as some of these substances may also be
ingested with other foods, like coffee in case of caffeine.
A more reliable approach to reach a high specificity
when assessing intake of a whole food group such as
SSBs might be to use a combination of exposure
markers as described by Gibbons et al. [95]. In this
study, a subcohort of 565 participants from the National
Adult Nutrition Survey was divided into four quartiles.
Four metabolites detected by NMR spectroscopy in
urine—formate, citrulline, taurine, and isocitrate—
showed concentration levels that differed significantly
between SSB consumers (n = 146) and non-consumers
(n = 391) as identified via a 4-day semi-weighed food
record. Levels of these same four metabolites also
showed transient and modest increase in an acute inter-
vention study (n = 10) after the consumption of one can
of cola. The authors detected all four markers in the cola
drink used for the acute intervention study. Although
found in the cola drink, none of these compounds are
normally added in a pure form so that they would most
likely originate from added flavor extracts. It also re-
mains questionable whether these markers are indicative
of intake of the whole group of SSBs or cola consump-
tion only. So-called energy drinks often contain taurine,
a sulfur-containing amino acid. Thus, taurine might
serve as a marker for this specific type of beverage.
However, it is unlikely that taurine is present in all typesof SSB. Furthermore, other sources of taurine cannot be
excluded. Taurine is formed in human metabolism from
methionine and cysteine with an endogenous average
daily synthesis of 0.4–1.0 mmol (50–125 mg) [96]. Meat
and seafood are significant dietary sources of this amino
acid [93]. Similarly, isocitrate is an intermediate of the
citric cycle—like citrate—and, therefore, occurs in all
humans, animals, and plants. These examples demon-
strate that the urinary excretion of these compounds can
have different origins that interfere with their use as
markers of exposure for SSBs. Further validation of the
proposed panel of biomarkers in other populations is
still necessary. Furthermore, more research is needed to
identify new markers or marker panels with higher spe-
cificity and selectivity.
In summary, biomarkers of sugar intake would not be
ideal biomarkers of SSB intake due the diversity of diet-
ary sources of sugar. One exception may be the 13C/12C
isotope ratio in countries where sugarcane and corn
sugar is more specifically used as SSB sugar. Other SSB
ingredients or combinations of ingredients might be
used as biomarkers of intake for SSBs or for specific
types of SSB. However, none of these biomarkers have
yet been validated in population studies.
Low-calorie-sweetened beverage biomarkers
No studies were identified which specifically aimed to
identify biomarkers of LCSB intake. Rather, many of the
studies investigated the impact of LCSB consumption on
health via the measurement of effect biomarkers in rela-
tion to metabolic syndrome [97], blood pressure [98],
and glycemic control [99, 100]. LCSB consumption was
found to influence the concentration of various com-
pounds including urinary hippuric acid excretion [101],
serum uric acid concentrations [102], and plasma free
fatty acid concentrations [103]. However, these bio-
markers are not specific to LCSBs; hippuric acid is a po-
tential marker of toluene exposure, as well as fruit and
vegetable intake, and serum uric acid and plasma free
fatty acids are endogenous compounds influenced by
factors other than LCSB intake. Therefore, utilization of
these biomarkers is unlikely to provide useful informa-
tion on LCSB intake owing to a lack of specificity. Sev-
eral advanced glycation end products were found to be
present in regular and, to a lesser extent, in diet cola
drinks. They are normally excreted via the urine, but
they are also confounded by other more significant diet-
ary sources of these compounds [104]. Brominated vege-
table oil (BVO) is used in North America as a clouding
agent in some soft drinks but is not permitted for use in
many other areas, including the European Union, owing
to concerns about bromine toxicity. Bendig et al.
assessed the BVO content of commonly consumed soft
drinks, and BVO was detected in only three out of the
Rothwell et al. Genes & Nutrition  (2018) 13:15 Page 13 of 18ten drinks investigated indicating that tissue bromine
concentrations would not serve as a reliable biomarker
of LCSB intake [105]. Eisner et al. assessed the citrate
and malate content of diet beverages in the context of
the treatment of nephrolithiasis (kidney stones) [106],
but these two organic acids are not specific for
LCSBs and may be directly influenced by other diet-
ary and non-dietary factors or may not be relevant
for all LCSBs.
Given that the term LCSB encompasses an array of
products including carbonated beverages, fruit cordials,
sweetened dairy products, and flavored teas, all of which
are likely to differ significantly in their composition, the
identification of a specific biomarker of intake which is
specific to all LCSBs as a single food group is likely to
be challenging. The low-calorie sweeteners (LCSs) them-
selves, common to a large diversity of LCSBs, may prove
to be the most useful biomarkers of LCSB intake. There
are eleven LCSs currently approved for use on the Euro-
pean market (Additional file 2: Table S1), and their use
extends to a wide range of foods other than LCSBs, as
well as non-dietary products such as oral hygiene prod-
ucts and e-cigarette fluids [107]. Although this may
complicate the use of LCSs as valid markers of LCSB in-
take, LCSBs are widely considered to be the primary
source of LCSs in the diet; and therefore, measurementTable 6 Metabolic fates of low-calorie sweeteners approved in the
Sweetener (CAS registry no.) Metabolic fate
Saccharin (81-07-2) Not metabolised, excreted unchang
Acesulfame-K (55589-62-3) Not metabolised, excreted unchang
Aspartame (22839-47-0) Hydrolysed to aspartic acid, phenyla
and methanol.
Cyclamate (139-05-9) 80% of the population do not meta
cyclamate. In 20%, it undergoes par
hydrolysis in the gut to cyclohexyla
Extent of hydrolysis varies between
within individuals.
Thaumatin (53850-34-3) Undergoes normal protein digestio
NHDC (20702-77-6) Metabolised by gut microflora to si
metabolites to naturally occurring f
Salt of aspartame-acesulfame
(106372-55-8)
Dissociates to individual sweeteners
digestive fluids and undergoes sam
metabolic fates.
Sucralose (56038-13-2) Not metabolised, excreted mainly
unchanged but 2% of absorbed po
excreted as conjugates.
Steviol glycosides† Bacterial hydrolysis in the gut to ste
which is then absorbed and excrete
as steviol glucuronide.
Advantam (714229-20-6) Converted to advantame acid and
mainly excreted as such with 2 min
metabolites.
CAS Chemical Abstract Service, NHDC neohesperidine dihydrochalcone, N/A not app
Expert Committee on Food Additives
aPrincipal route of excretion listed
†No CAS registry, not availableof these as biomarkers may provide a viable option for
assessing LCSB intake.
The potential application of a biomarker approach for
investigating intakes of low-calorie sweeteners (LCS) has
recently been reviewed [107]. The metabolic fate of each
LCS is assessed prior to approval for use as a food addi-
tive (Table 6); and therefore, a targeted approach may be
implemented for those that lend themselves well to
analyses. A number of LCSs are excreted in urine in the
same form as found in the LCSBs. Acesulfame-K [108]
and saccharin [109–111] are almost completely absorbed
and excreted unchanged via the urine. The usefulness of
urinary excretions of these two LCSs as biomarkers of
intake was investigated by Wilson et al. who measured
levels of excretion in 24-h urine samples and found high
correlation with acute intakes of saccharin and
acesulfame-K in an intervention study with five different
doses of the LCS (R2 > 0.99 for both compounds), dem-
onstrating a clear dose-response relationship for both
compounds [112]. Two other LCSs, cyclamate [113] and
sucralose [114, 115], are partially absorbed (respectively
30–50 and 10–15%) and subsequently excreted un-
changed in urine. A proportion of cyclamate is con-
verted to cyclohexylamine via bacterial hydrolysis in the
gut in around 20% of the population. This is then
absorbed and excreted via the urine [116]. The processEuropean Union (adapted from [107])
Route(s) of excretiona References
ed. Urine [109, 110]
ed. Urine [108]
lanine N/A [121, 122]
bolise
tial
mine.
and
Faeces, urine [113]
n. N/A [123]
milar
lavonoids.
Urine [124]
in
e
See information for
acesulfame-K and aspartame
[134]
rtion
Faeces, urine [114, 115]
viol
d
Urine [117–119]
or
Faeces, urine [120]
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tween and within individuals, particularly during chronic
exposure [113]; and therefore, some doubt must be cast
on its usefulness as a reliable marker of cyclamate intake
in the free-living population. A relatively new and increas-
ingly used LCS, a mixture of steviol glycosides isolated
from the leaf of Stevia rebaudiana, undergoes bacterial
hydrolysis in the gut prior to absorption and subsequent
excretion in urine as steviol glucuronide [117–119].
Advantame is deesterified to advantame acid and a small
proportion is absorbed (~ 6%) and excreted via the urine
[120]. The excretion products of acesulfame-K, saccharin,
sucralose, cyclamates, steviol glycosides, and advantame
are highly specific to exposures to the parent compound
per se as they are not produced endogenously. Therefore,
any detection of these in urine would indicate intake of
the related sweeteners. However, further work would be
required to assess their specificity as biomarkers of LCSB
intake.
Other LCSs, namely aspartame, neohesperidine dihy-
drochalcone (NHDC), and thaumatin, undergo extensive
metabolism into metabolites commonly found in the
diet or in the body, which suggests that no obvious spe-
cific biomarkers of intake exist for these LCSs. Aspar-
tame is broken down to its three constituents, aspartic
acid, phenylalanine, and methanol, all of which are often
present in greater quantities in other dietary sources
[121, 122]. Thaumatin, a naturally occurring protein
complex, undergoes normal protein digestion; and there-
fore, identification of a specific biomarker of intake is
not likely to be possible [123]. Finally, NHDC has a
similar structure to naturally occurring flavonoids with
similar metabolites; and for this reason, specificity of any
putative biomarker is likely to be problematic [124].
In summary, a biomarker approach for assessing intake
of specific LCSs used in LCSBs may prove useful as sev-
eral of them are excreted unchanged in urine following in-
gestion. Expected biomarkers should be based on LCSs
most commonly used in LCSBs. However, considering the
range of LCSs used in different types of LCSBs, the
geographical differences and the evolving nature of LCS
use by manufacturers, further work is required to ensure
the specificity of the putative biomarkers. This work may
take the form of comprehensive and international label
surveys along with biomarker validation studies for spe-
cific LCSBs. As such, more work will be needed to validate
their use as biomarkers of LCSB intake, considering all
these factors, and to identify possible confounding by
other foods containing the same LCSs.
Conclusions
A wide diversity of biomarkers has been proposed to
estimate the consumption of non-alcoholic beverages.
Metabolism of major constituents of non-alcoholic beverageshas been studied in a large number of controlled intervention
studies, and many metabolites were identified mainly in
blood and urine (Tables 1 and 2). Participants in these stud-
ies have usually consumed a high amount of a particular bev-
erage with a fully controlled diet after a proper washout
period. These studies are useful for identification of putative
biomarkers of intake, but provide limited evidence of their
potential value as biomarkers of intake in a population and
more particularly of their sensitivity and specificity.
Several of these candidate biomarkers have been fur-
ther studied in observational studies with individuals
following their own diet and their sensitivity and specifi-
city as indicators of coffee, tea, and SSB intake evaluated
(Tables 1, 2, and 3). Various compounds including phen-
olic acids, alkaloids, and terpenes measured in urine or
plasma samples were shown to accurately predict coffee
intake in various populations, and EGC and 4-O-methyl-
gallic acid were also shown to be good indicators of tea
intake. These two last biomarkers could also possibly be
used to differentiate intake of green and black tea.
Several biomarkers have been proposed to estimate SSB
intake but none for LCSB intake. Difficulties met in find-
ing biomarkers for these two last classes of beverages
are explained by the lack of constituents that would be
at the same time characteristic of each of these two
groups of beverages and absent in all other foods.
Controlled intervention studies and observation studies
are complementary. The first ones provide direct evidence
of the causality of the associations between beverage intake
and the biomarker and allow establishing the dose-effect
relationship. Observational studies, although relying on
self-reported estimate of beverage intake that are liable to
errors, allow to study the sensitivity and selectivity of a
biomarker and to identify potential confounders.
Combinations of biomarkers may be needed to assess
intake of SSBs and LCSBs. Combinations of biomarkers
may also allow the estimation of intake of different types
of beverages within a particular group, as suggested for
green and black tea. Combination of a generic biomarker
for coffee with caffeine should help assess relative intake
of caffeinated and decaffeinated coffee. Panels of bio-
markers of intake have been proposed, but none has yet
been validated.
The new biomarkers, identified through metabolomics
or other approaches, will need to be validated in popula-
tions sharing similar lifestyle and diet to the ones where
these biomarkers will be used. All possible confounders
(e.g., foods containing the same biomarker or a precursor
transformed into the biomarker in the body) will need to
be carefully considered [37]. More extensive food compos-
ition data for these compounds, often scattered across a
large number of publications and not easily analyzed, will
have to be collected and made easily accessible in new da-
tabases such as those developed for polyphenols or for
Rothwell et al. Genes & Nutrition  (2018) 13:15 Page 15 of 18caffeine [59, 125]. Biomarkers with long elimination
half-lives should be preferred particularly to assess intakes
of foods more episodically consumed [126] although this
may be less important for beverages like coffee or tea most
often consumed on a daily basis [37]. Finally, the practical-
ity of biomarkers will need to be assessed, including their
performance according to the type of biospecimens (e.g.,
urine vs. blood, fasting vs. non-fasting blood samples or
24-h urine samples vs. spot urine samples), performance
of analytical methods, and cost of analyses.
Overall, biomarkers should help estimate intake of
non-alcoholic beverages and this may be particularly
useful in overcoming some of the limitations met with
dietary questionnaires. It is expected that these bio-
markers will be increasingly used in cohort studies to
evaluate the effects of non-alcoholic beverages on dis-
ease risk. However, it will also be important to carefully
evaluate the respective advantages of biomarkers and
questionnaires, an evaluation that has not been done yet.
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